Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements-Reference-Cited by-同舟云学术

Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements

Published:2022-05-12 Issue:5 Volume:5 Page:e225996
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Spetz Joanne¹²³⁴⁵,Hailer Laurie⁶,Gay Caryl⁷,Tierney Matthew⁵,Schmidt Laura¹⁸,Phoenix Bethany⁵,Chapman Susan¹²⁴

Affiliation:

1. Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco

2. Healthforce Center at UCSF, University of California, San Francisco

3. Department of Family and Community Medicine, University of California, San Francisco

4. Department of Social and Behavioral Sciences, University of California, San Francisco

5. Department of Community Health Systems, University of California, San Francisco

6. Quantgal LLC, Fairfax, California

7. Department of Family Health Nursing, University of California, San Francisco

8. Department of Humanities and Social Sciences, University of California, San Francisco

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2792222/spetz_2022_ld_220050_1651764567.03214.pdf

Reference6 articles.

1. Emergency department utilization for substance use disorders and mental health conditions during COVID-19.;Venkatesh;PLoS One,2022

2. Practice guidelines for the administration of buprenorphine for treating opioid use disorder.;Fed Regist,2021

3. Why aren’t physicians prescribing more buprenorphine?;Huhn;J Subst Abuse Treat,2017

4. Treating patients with opioid use disorder in their homes: an emerging treatment model.;Uscher-Pines;JAMA,2020

5. Drug Addiction Treatment Act of 2000, H.R. 2634, 106th United States Congress, 2nd sess (Hatch O, Biden J, Levin C 2000). Published July 27, 2000. Accessed March 1, 2022. https://www.congress.gov/106/bills/hr2634/BILLS-106hr2634pcs.pdf

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements;JAMA Network Open;2024-08-05

2. Reducing perceived barriers to scaling up overdose education and naloxone distribution and medications for opioid use disorder in the United States in the HEALing (Helping End Addiction Long-Term®) communities study;Preventive Medicine;2024-08

3. Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency;Journal of Substance Use and Addiction Treatment;2024-07

4. Growing importance of high-volume buprenorphine prescribers in OUD treatment: 2009–2018;Drug and Alcohol Dependence;2024-06

5. Tools to implement measurement-based care (MBC) in the treatment of opioid use disorder (OUD): toward a consensus;Addiction Science & Clinical Practice;2024-02-28